- Eckert & Ziegler SE recorded sales growth to € 68.2 million in the first quarter of 2025 compared to € 67.6 million in the previous year.
- EBIT before special items rose by 8% to € 16.2 million, while net profit increased by 14% to € 9.7 million.
- Despite a cyberattack and a short-term delivery stop for gallium generators, the company was able to confirm its annual forecast for 2025 with sales of around € 320 million and EBIT of around € 78 million.
- Sales in the Medical segment remained stable at € 34.4 million, with pharmaceutical radioisotopes being the most important revenue driver.
- The Isotope Products segment achieved a slight increase in sales of 2% to € 33.8 million.
Eckert & Ziegler SE is a leading provider of isotope technology components for nuclear medicine and radiotherapy and is listed on the TecDAX of the German Stock Exchange.
https://www.ezag.com/wp-content/uploads/2025/05/EZAG_Q1-2025.pdf
